AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24279707 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA exposure with progression of blood pulse pressure (pp)
Number of subjects: 0
Study 24279707 — intervention group
Group type: EXPERIMENTAL
Intervention: High 6M pulse pressure (≥ 60 mmHg)
Number of subjects: 0
Study 24279707 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA maintenance
Number of subjects: 0
Study 22799523 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) using the MDRD equation
Number of subjects: 1239
Study 22799523 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) using the CKD-EPI equation
Number of subjects: 1239
Study 22799523 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of eGFR by the MDRD equation to Framingham risk factors
Number of subjects: 1239
Study 19155372 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisynthetic penicillins (SSPs) including amoxicillin, ampicillin, pivampicillin
Number of subjects: 287
Study 19155372 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-based regimens (trimethoprim, trimethoprim-sulfamethoxazole, trimethoprim-sulfadiazine)
Number of subjects: 287
Study 17448413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (20 mg daily)
Number of subjects: 116
Study 17448413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 15535495 — intervention group
Group type: EXPERIMENTAL
Intervention: gum elastic bougie-guided technique
Number of subjects: 100
Study 15535495 — intervention group
Group type: COMPARATOR
Intervention: introducer tool technique
Number of subjects: 100
Study 11555062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg once daily for 6 weeks
Number of subjects: 548
Study 10021957 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg‐1 po
Number of subjects: 60
Study 8150109 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (Gonal‐F)
Number of subjects: 12
Study 8150109 — intervention group
Group type: COMPARATOR
Intervention: Urinary human FSH
Number of subjects: 12
Study 2852485 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha Con1 3 MU
Number of subjects: 119
Study 2852485 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha Con1 9 MU
Number of subjects: 119
Study 2852485 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha Con1 30 MU
Number of subjects: 119
Study 2852485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 31707628 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular symphysis combined with beta-tricalcium phosphate (MS+TCP)
Number of subjects: 31
Study 31707628 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest (IC)
Number of subjects: 31
Study 31707628 — intervention group
Group type: COMPARATOR
Intervention: Mandibular symphysis (MS)
Number of subjects: 31
Study 29036439 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage tailored intervention (ST)
Number of subjects: 1243
Study 29036439 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stage tailored intervention (NST)
Number of subjects: 1243
Study 29036439 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 1243
Study 28160494 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg - Droperidol 5 mg
Number of subjects: 92
Study 28160494 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 10 mg
Number of subjects: 92
Study 28160494 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 10 mg
Number of subjects: 92
Study 23985247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received diabetes factsheets and a DVD comprising patient stories (narratives) of type 2 diabetes management.
Number of subjects: 670
Study 23985247 — intervention group
Group type: COMPARATOR
Intervention: Control group received factsheets only.
Number of subjects: 670
Study 23303067 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias-related brain activity measured with a cocaine Stroop task in the dorsal anterior cingulate cortex (dACC)
Number of subjects: 0
Study 23303067 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving in the week before treatment
Number of subjects: 0
Study 23303067 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain activity in the dACC
Number of subjects: 0
Study 21499196 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched total parenteral nutrition (GE-TPN) solution consisting of 0.4 g/kg/day of l-alanine-glutamine dipeptide
Number of subjects: 120
Study 21499196 — intervention group
Group type: COMPARATOR
Intervention: Standard total parenteral nutrition (S-TPN)
Number of subjects: 120
Study 21499196 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched total parenteral nutrition (GE-TPN) solution
Number of subjects: 120
Study 18000176 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day pioglitazone for 16 weeks
Number of subjects: 30
Study 18000176 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 30
Study 15227689 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length Medi thrombexin climax stockings
Number of subjects: 376
Study 15227689 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-length thrombexin climax stockings
Number of subjects: 376
Study 15227689 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length Kendall T.E.D. stockings
Number of subjects: 376
Study 15227689 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH thromboprophylaxis
Number of subjects: 376
Study 9989513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pion radiation therapy
Number of subjects: 217
Study 9989513 — intervention group
Group type: COMPARATOR
Intervention: Conventional external beam photon therapy
Number of subjects: 217
Study 7590426 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 degrees C drink
Number of subjects: 12
Study 7590426 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 degrees C drink
Number of subjects: 12
Study 7590426 — intervention group
Group type: COMPARATOR
Intervention: 37 degrees C drink
Number of subjects: 12
Study 7590426 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (350 ml)
Number of subjects: 12
Study 7590426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie orange cordial (50 ml)
Number of subjects: 12
Study 1713895 — intervention group
Group type: EXPERIMENTAL
Intervention: Autooxygenation (group A)
Number of subjects: 40
Study 1713895 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator (group B)
Number of subjects: 40
Study 449951 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B and flucytosine combination therapy
Number of subjects: 50
Study 449951 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B alone
Number of subjects: 50
Study 31661438 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite mesh (Ventralex Patch)
Number of subjects: 61
Study 31661438 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh (on-lay)
Number of subjects: 61
Study 31661438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 28260702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg) twice daily
Number of subjects: 32
Study 28260702 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (50 mg) once daily
Number of subjects: 32
Study 26542503 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided intervention
Number of subjects: 2000
Study 26542503 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided intervention
Number of subjects: 2000
Study 24982457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection with brachytherapy (SRB)
Number of subjects: 222
Study 24982457 — intervention group
Group type: COMPARATOR
Intervention: Sublobar resection (SR)
Number of subjects: 222
Study 24982457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection with brachytherapy (SRB) in patients with positive staple line cytology
Number of subjects: 222
Study 21915042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic-floor muscle exercise (PFME) started after catheter removal post-RP
Number of subjects: 62
Study 21915042 — intervention group
Group type: COMPARATOR
Intervention: Control group taught PFME in the third month after RP
Number of subjects: 62
Study 19172346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed ePTFE grafts (Venaflo)
Number of subjects: 89
Study 19172346 — intervention group
Group type: COMPARATOR
Intervention: Noncuffed ePTFE grafts (Stretch Gore-Tex)
Number of subjects: 89
Study 17384502 — intervention group
Group type: EXPERIMENTAL
Intervention: MP catheter via MP technique (group A)
Number of subjects: 214
Study 17384502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenckhoff catheters via MP technique (group B)
Number of subjects: 214
Study 17384502 — intervention group
Group type: COMPARATOR
Intervention: Tenckhoff catheters via conventional technique (group C)
Number of subjects: 214
Study 15193811 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) therapy
Number of subjects: 45
Study 15193811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11208941 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of oral Lipiodol
Number of subjects: 305
Study 11208941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 9892029 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP education program
Number of subjects: 1041
Study 9892029 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP education materials
Number of subjects: 1041
Study 7985254 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance‐positive expiratory pressure (IR‐PEP)
Number of subjects: 160
Study 7985254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 160
Study 7985254 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 160
Study 7985254 — intervention group
Group type: COMPARATOR
Intervention: Standard chest physiotherapy (control)
Number of subjects: 160
Study 2736096 — intervention group
Group type: EXPERIMENTAL
Intervention: lip shave
Number of subjects: 40
Study 2736096 — intervention group
Group type: EXPERIMENTAL
Intervention: carbon dioxide laser ablation
Number of subjects: 40
Study 2736096 — intervention group
Group type: COMPARATOR
Intervention: chemical peel with trichloroacetic acid
Number of subjects: 40
Study 2736096 — intervention group
Group type: COMPARATOR
Intervention: topical fluorouracil
Number of subjects: 40
Study 31116102 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with diaphragmatic breathing and biofeedback therapy
Number of subjects: 0
Study 31116102 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0
Study 31116102 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen at a dose of 10 mg three times daily
Number of subjects: 0
Study 28179221 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sugar-sweetened beverage consumption
Number of subjects: 20
Study 25589306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (4 cycles of 1-min balloon occlusion separated by 1 min of deflation)
Number of subjects: 111
Study 25589306 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary PCI (control group)
Number of subjects: 111
Study 25589306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 111
Study 23458405 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300 mg/day for 40 days)
Number of subjects: 20
Study 23458405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21819545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) ∼1,000 kcal/day
Number of subjects: 31
Study 21819545 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet, low-fat, reduced-carbohydrate, prescribed to decrease intake by ∼600 kcal/day
Number of subjects: 31
Study 19160733 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17535863 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 64
Study 17535863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15355146 — intervention group
Group type: EXPERIMENTAL
Intervention: Category tasks with a single relevant dimension
Number of subjects: 0
Study 15355146 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptually chaotic tasks requiring exemplar memorization
Number of subjects: 0
Study 15355146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks based in XOR relations
Number of subjects: 0
Study 11728627 — intervention group
Group type: COMPARATOR
Intervention: Subjects who withdrew consent
Number of subjects: 70
Study 11728627 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched retained subjects
Number of subjects: 70
Study 11728627 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched subjects who completed all required visits
Number of subjects: 70
Study 10518851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide mouthrinse
Number of subjects: 12
Study 10518851 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 12
Study 7979805 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected seminal fructose measurement in leucocytospermics
Number of subjects: 33
Study 7979805 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum testosterone measurement
Number of subjects: 33
Study 7979805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measurement of serum testosterone and corrected seminal fructose
Number of subjects: 33
Study 7979805 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal prolactin levels in leucocytospermic subjects
Number of subjects: 33
Study 7979805 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of obstructive process
Number of subjects: 33
Study 2661607 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15
Study 31098639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 12 weeks gestational age (wkGA)
Number of subjects: 519
Study 31098639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 20 wkGA
Number of subjects: 519
Study 31098639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 28 wkGA
Number of subjects: 519
Study 31098639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 36 wkGA
Number of subjects: 519
Study 31098639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroxyglutamate at 24-28 wkGA
Number of subjects: 519
Study 31098639 — intervention group
Group type: COMPARATOR
Intervention: PAPP-A at 12 wkGA
Number of subjects: 519
Study 31098639 — intervention group
Group type: COMPARATOR
Intervention: Placenta growth factor at 12 wkGA
Number of subjects: 519
Study 30814417 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin ingestion (180 mg/d) 4 d after exercise (POST)
Number of subjects: 24
Study 30814417 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin ingestion (180 mg/d) 7 d before exercise (PRE)
Number of subjects: 24
Study 30814417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (180 mg/d) 4 d after exercise (CON)
Number of subjects: 24
Study 28857279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol-containing chewing gum (with or without Magnolia bark extract)
Number of subjects: 0
Study 28857279 — intervention group
Group type: COMPARATOR
Intervention: Parafilm (control)
Number of subjects: 0
Study 25288035 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 821
Study 23507997 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of 60-min exercise (50% VO2 peak)
Number of subjects: 38
Study 23507997 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 38
Study 21205939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial administration of BM‐MNC
Number of subjects: 40
Study 21205939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21205939 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated BM‐MNC administration
Number of subjects: 40
Study 21205939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BM‐MNC numbers and functionality
Number of subjects: 40
Study 21205939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer healing induced by repeated BM‐MNC administration
Number of subjects: 40
Study 18434158 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf heel inserts
Number of subjects: 35
Study 18434158 — intervention group
Group type: COMPARATOR
Intervention: No inserts
Number of subjects: 35
Study 17119141 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard open diskectomy
Number of subjects: 743
Study 17119141 — intervention group
Group type: COMPARATOR
Intervention: Usual nonoperative care
Number of subjects: 743
Study 15327525 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 256
Study 15327525 — intervention group
Group type: COMPARATOR
Intervention: Low dose coumadin (1 mg/d)
Number of subjects: 256
Study 15327525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH, enoxaparin 40 mg s.c. q.d.)
Number of subjects: 256
Study 15327525 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide with full anticoagulation
Number of subjects: 256
Study 15327525 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide and chemotherapy during consolidation treatment
Number of subjects: 256
Study 11416876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 15
Study 11416876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9052314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium
Number of subjects: 62
Study 9052314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg cisatracurium
Number of subjects: 62
Study 9052314 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg vecuronium
Number of subjects: 62
Study 8134772 — intervention group
Group type: EXPERIMENTAL
Intervention: Five doses of ivermectin
Number of subjects: 893
Study 8134772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ivermectin
Number of subjects: 893
Study 8134772 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 893
Study 3526522 — intervention group
Group type: EXPERIMENTAL
Intervention: TL-102 (beclomethasone dipropionate powder preparation) 50 micrograms with 30 micrograms of hydroxypropylcellulose, administered intranasally at a dose of 2 capsules/day b.i.d. for one week
Number of subjects: 250
Study 3526522 — intervention group
Group type: EXPERIMENTAL
Intervention: TL-102 (beclomethasone dipropionate powder preparation)
Number of subjects: 250
Study 3526522 — intervention group
Group type: COMPARATOR
Intervention: Conventional BDP preparations
Number of subjects: 250
Study 29771450 — intervention group
Group type: EXPERIMENTAL
Intervention: AHM trial
Number of subjects: 23
Study 29771450 — intervention group
Group type: COMPARATOR
Intervention: PLAC trial
Number of subjects: 23
Study 29771450 — intervention group
Group type: COMPARATOR
Intervention: PLAC+EXER trial
Number of subjects: 23
Study 29771450 — intervention group
Group type: EXPERIMENTAL
Intervention: AHM+EXER trial
Number of subjects: 23
Study 27055601 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin 10 μg twice daily
Number of subjects: 204
Study 27055601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 25027701 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin supplementation (10 mg/day for 7 days, then 5 mg daily until day 42)
Number of subjects: 630
Study 25027701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical oral placebo)
Number of subjects: 630
Study 25027701 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamin supplementation
Number of subjects: 630
Study 25027701 — intervention group
Group type: COMPARATOR
Intervention: Thiamin supplementation and Placebo
Number of subjects: 630
Study 22695018 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microplate (subapical) and 1 miniplate (at the lower border)
Number of subjects: 20
Study 22695018 — intervention group
Group type: COMPARATOR
Intervention: 2-miniplate protocol
Number of subjects: 20
Study 22695018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1 microplate + 1 miniplate and 2-miniplate)
Number of subjects: 20
Study 22695018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 20187947 — intervention group
Group type: EXPERIMENTAL
Intervention: Early medication change (EMC) strategy
Number of subjects: 0
Study 20187947 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 18176739 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with spinal cord injury
Number of subjects: 545
Study 18176739 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 545
Study 16307968 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (Leuprorelin 3.75 mg/28 days)
Number of subjects: 26
Study 16307968 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal progestin implant (etonogestrel 68 mg)
Number of subjects: 26
Study 16307968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 12660529 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 131
Study 12660529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 131
Study 12660529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Nelfinavir and Efavirenz
Number of subjects: 131
Study 10714913 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (750 mg)
Number of subjects: 146
Study 10714913 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg
Number of subjects: 146
Study 10714913 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg
Number of subjects: 146
Study 10714913 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 microg
Number of subjects: 146
Study 10714913 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 microg
Number of subjects: 146